Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
139 hedge funds and large institutions have $1.11B invested in Endocyte, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 46 increasing their positions, 32 reducing their positions, and 12 closing their positions.
208% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 12
192% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $4.32M
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
52% more capital invested
Capital invested by funds: $728M → $1.11B (+$378M)
44% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 32
22% more funds holding
Funds holding: 114 → 139 (+25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$36.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$30.2M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$27.6M |
| 4 |
DM
Deerfield Management
New York
|
+$20.4M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$65.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11M |
| 3 |
D.E. Shaw & Co
New York
|
-$10.3M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$6.76M |
| 5 |
VMI
VHCP Management II
New York
|
-$1.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PIA
151
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$16K | -1,129 | Closed |
|
152
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$3K | -233 | Closed |
|
ECYT Hedge Fund Activity: Q3 2018 in Review
139 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q3 2018, worth a combined $1.11B — up 52% from $728M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ECYT positions and 12 closed out — a net gain of 25 holders — while 46 added to existing stakes and 32 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $36.2M. The largest seller was PFM Health Sciences, cutting an estimated $65.8M.
- 139 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q3 2018, up from 114 in Q2 2018.
- Funds reported $1.11B of Endocyte, Inc. Common Stock stock for Q3 2018, up 52% quarter-over-quarter.
- 37 funds opened new Endocyte, Inc. Common Stock positions in Q3 2018 and 12 closed out, a net change of +25 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q3 2018 was Point72 Asset Management, an estimated $36.2M added.
- The largest Endocyte, Inc. Common Stock seller in Q3 2018 was PFM Health Sciences, an estimated $65.8M sold.
Based on aggregated 13F filings for Q3 2018.